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Mitochondria are highly dynamic organelles that are important for many diverse cellular processes, such as energy metabolism,
calcium buﬀering, and apoptosis. Mitochondrial biology and dysfunction have recently been linked to diﬀerent types of cancers
and neurodegenerative diseases, most notably Parkinson’s disease. Thus, a better understanding of the quality control systems
that maintain a healthy mitochondrial network can facilitate the development of eﬀective treatments for these diseases. In this
perspective, we will discuss recent advances on two mitochondrial quality control pathways: the UPS and mitophagy, highlight
how new players may be contributing to regulate these pathways. We believe the proteases involved will be key and novel regulators




Parkinson’s disease (PD) is a neurodegenerative disease of
the central nervous system that results from the loss of
dopaminergic neurons in the substantia nigra (SN) region
of the brain. While environmental factors such as oxidative
and nitrosative stress are responsible for the, more common,
sporadic form of PD [1], there are genetic factors that
contribute to the familiar (genetic) form of the disease [2].
Both forms of PD are characterized by the formation of
Lewy bodies (LBs)—aggregates of various proteins including
alpha-synuclein, ubiquitin, and tubulin. Although the mech-
anism that leads to PD pathogenesis remains elusive, studies
have shown that mitochondrial dysfunction plays a role in
the progression of both forms of the disease [2–4].
Mitochondria are vital for many diverse processes in
the cell, such as energy metabolism, calcium buﬀering, and
cell apoptosis. These double-membrane-bound organelles
are often called the “powerhouses” of the cell because they
generate the cell’s supply of energy in the form of ATP. They
are also the main source of reactive oxygen species (ROS)
and therefore are most susceptible to damage by oxidative
stress. An accumulation of ROS can lead to mutations
in mitochondrial DNA and misfolding and aggregation
of proteins, which can disrupt normal functions [5]. It
is known that neuronal cells are particularly vulnerable
to the functional deterioration of mitochondria, primarily
due to their high-energy demands. Consequently, along
with PD, mitochondrial dysfunction has been linked to
other neurodegenerative diseases such as Alzheimer’s and
Huntington’s disease, and the pathways discussed below may
be applicable [6–8].
Since proper functioning mitochondria are required for
various cellular processes, it is not surprising that there
are several quality control systems that work to main-
tain a healthy mitochondrial population. Mitochondria are
constantly undergoing fusion and ﬁssion events; the exact
reason for these dynamics is not currently known, but it is
thought they serve to monitor and protect the integrity of
the mitochondrial network. Fusion, the merging of distinct
mitochondria, enables the mixing and dilution of defective
proteins,whileﬁssionfacilitatesthedivisionandthesegrega-
tion of severely damaged areas [9, 10]. In addition, in each of
its compartments, the mitochondrion houses proteases that
degrade misfolded and/or dysfunctional proteins [9].
Recent studies have revealed that the ubiquitin protea-
some system (UPS) also participates in recycling mitochon-
drial-associated proteins (see reviews [11–14]). The UPS is a
primarily cytosolic system that eliminates impaired and/or2 Parkinson’s Disease
nonfunctional proteins in the cell. It involves the covalent
attachment of a 76-amino acid protein, called ubiquitin.
Ubiquitination of a protein occurs via three sequential steps:
(i) ubiquitin activation by E1 enzymes, (ii) conjugation to
a carrier by E2 enzymes, and (iii) ligation of ubiquitin to
the target by E3 ligases. Once a substrate is tagged with
K48-linked polyubiquitin chains, it is degraded by the 26S
proteasome. Conversely, deubiquitinating enzymes (DUBs)
appear to drive the pathway in reverse by opposing the func-
tionofE3ligasesbyremovingoreditingtheubiquitinchains.
While new lines of evidence indicate that the UPS
is important for the removal of individual mitochondrial
proteins, the autophagy-lysosome pathway (ALP) is respon-
sible for the degradation of the organelle as a whole
[15]. Autophagy can be subcategorized into three forms:
macroautophagy, microautophagy, and chaperone-mediated
autophagy [16]. The form that is of interest to us and the
ﬁeld of mitochondrial dynamics and quality control is a
selective type of macroautophagy, called mitophagy, which
mediates the removal of damaged mitochondria that can
be toxic to the cell [17, 18]. The initial step in mitophagy
entails recruiting double-membrane-bound vesicles called
autophagosomes [19]. These structures ﬁrst engulf mito-
chondria and the surrounding cytosolic constituents and
then subsequently fuse with the lysosome, which degrades
the sequestered cargo [16]. In yeast, mitophagy can be
mediated by the autophagy-related protein Atg 32, amongst
several other Atg proteins [20]. In mammalian systems,
mitophagy can be initiated through diﬀerent mechanisms,
such as NIX in maturating red blood cells [21] and the
PINK1/Parkin pathway[17], whichwill be discussed in more
detail in subsequent sections.
The multiplicity of quality control systems reﬂects the
high level of complexity and intricacy of design, but this
makes it diﬃcult to elucidate exactly how mitochondrial
dysfunction contributes to neurodegeneration. In this per-
spective, we will present key discoveries in two distinct
yet interconnected mitochondrial quality control systems:
the UPS and mitophagy. The hypotheses proposed here,
regarding novel regulators within these pathways, will serve
as a starting point for further studies on the subject. Notably,
wehighlightthatseveralimportantproteasesmightbeimpli-
cated in orchestrating the overall pathway of mitochondrial
homeostasis. A better understanding of the systems at play
and their relationship with mitochondrial metabolism and
intrinsic proapoptotic events may lead to the development of
novel screening tools and therapeutic treatments for several
debilitating neurodegenerative human diseases like PD.
2.TheUPS andMitochondrial
Protein Degradation
2.1. Several Mitochondrial Proteins Are Proteasomal Sub-
strates. The UPS has recently been linked to mitochondrial
function as a part of its overall quality control system.
The initial evidence that implicates the UPS in mitochon-
drial protein degradation comes from proteomic screens
of mitochondria that have identiﬁed over 100 proteins
that can undergo ubiquitination [13, 22, 23]. The proteins
identiﬁed are important for various mitochondrial functions
such as ATP production by oxidative phosphorylation and
biosynthesis of fatty acids [13]. Protein ubiquitination is a
posttranslational modiﬁcation that can lead to proteasomal
degradation, alter speciﬁc cellular localization, or control
other regulatory outcomes in the cell such as immune
signalling and cell cycle and division [24]. In addition,
the mitochondrial ubiquitinome may consist of nuclear-
encoded proteins that are ubiquitinated for their import
into the mitochondria. As shown by Zhaung and McCauley,
ubiquitin conjugation of monoamine oxidase B serves as a
signal for its import into mitochondria [25].
Themitochondrialubiquitinomemayalsorepresentpro-
teins that have been marked for clearance by the cytoplasmic
26S proteasome. There is increasing evidence to support
this latter view that the proteasome functions to eliminate
defective proteins in the cytosol that were destined for
the mitochondria to prevent the import of damaged cargo
(Figure 1(a)). Alternatively, and perhaps simultaneously, the
proteasome is responsible for the degradation of proteins
at the mitochondria, more speciﬁcally proteins on the
OMM that share an interface with the cytoplasm. Well-
studied examples of OMM proteins that are degraded in a
proteasome-dependent manner include Mcl1, a prosurvival
member of the Bcl-2 family [26, 27]; Drp1, a mitochondrial
ﬁssion protein [28]; mitofusins 1/2, regulators of mitochon-
drial fusion [29, 30]. These observations highlight the inﬂu-
ence of the UPS in regulating apoptosis and mitochondrial
membrane dynamics. It is likely that these processes will also
be required for several homeostatic pathways during normal
development and cellular diﬀerentiation, underscoring the
importance of proteolytic regulators.
2.2. Non-OMM Proteasomal Substrates. Surprisingly, new
research has shown that the UPS may also play a role in
the degradation of non-OMM proteins. Margineantu et al.
reported that proteasome inhibition with MG132 leads to
increased mitochondrial mass, which may be attributed to
an accumulation of IMM-localized proteins [31]. Consistent
with these ﬁndings, speciﬁc targets of the proteasome that
have been identiﬁed include endonuclease G, an IMS protein
[32]. Additionally, two integral IMM proteins, UCP2 and
3, were shown to be degraded by the 26S proteasome after
undergoingK48-linkedpolyubiquitylation[33,34].Remark-
ably, it was found that the mitochondrial matrix localized
oligomycin sensitivity-conferring protein (OSCP) is also
degraded in a proteasome-dependent manner, with the help
ofhsp90[31].Takentogether,thesestudiesindicate,contrary
to popular belief, that proteasome-mediated degradation
is not restricted to OMM proteins; proteins in the IMS,
IMM, and matrix are also candidate substrates for the 26S
proteasome (Figure 1(b)).
2.3. Molecular Steps of the UPS at Mitochondria. The exact
mechanisms that govern proteasome-mediated turnoverParkinson’s Disease 3
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Figure 1: A model of UPS-mediated mitochondrial protein degradation. (a) Damaged and/or misfolded nuclear-encoded proteins that
are destined for import into the mitochondria are intercepted by E3 ubiquitin ligases and labeled with K48-linked polyubiquitin chains.
Subsequently, these proteins undergo degradation by the cytoplasmic 26S proteasome. Only the substrate alone is degraded, while ubiquitin
is recycled by one or more of the proteasomal-speciﬁc deubiquitinating enzymes (DUBs, shown in red). (b) The turnover of proteins that
are already at the mitochondria occurs via a process called mitochondria-associated degradation (MAD). Defective proteins at the OMM
are polyubiquitinated by E3 ligases. These proteins are then extracted from the membrane by the AAA-ATPase p97 and delivered to the
proteasome for proteolysis. Alternatively, mitochondrial-associated DUBs may rescue proteins from degradation by editing or removing the
degradative ubiquitin signal. Hence, DUBs may enhance the stability of mitochondrial proteins. In addition, many lines of evidence suggest
that the UPS also facilitates the degradation of non-OMM proteins. However, the mechanistic details of how proteasomal substrates within
inner compartments retrotranslocate to the OMM have not yet been established.
of mitochondrial proteins remain undeﬁned. Nevertheless,
there is a proposed pathway that is based on another
membrane-enclosed organelle, the endoplasmic reticulum
(ER). The ER-associated degradation (ERAD) pathway is a
multistep process that allows the 26S proteasome to extract
and breakdown proteins that are normally conﬁned by
the ER membrane. This process requires Cdc48 (known
as p97 in mammals) and the adaptor proteins Np14 and
Ufd1 [11]. Similarly, following a loss of mitochondrial
membrane potential, p97 has been shown to accumulate on
the mitochondria in order to chaperone polyubiquitinated
proteinstotheproteasome,inaprocesscalledmitochondria-
associated degradation (MAD) (Figure 1(b))[ 30, 35]. In
yeast, under stress conditions, Vms1 is translocated from
the cytosol to the mitochondria, where it engages Cdc48/p97
[36]. Although mammalian Vms1 has been shown to purify
with p97, it is unclear whether it is required to recruit p97
and initiate MAD. Interestingly, a subset of p97 localizes
to the mitochondria under normal conditions, suggesting
that it is required to maintain a steady state of proteasomal
degradation likely promoting a homeostatic checkpoint to
ensure mitochondrial ﬁdelity.
Several questions remain to be addressed regarding the
molecularpathwayofthemitochondrialUPS.Themolecular
machinery that retrotranslocates proteins from the inner
compartments to the OMM has not been deﬁned. Like with
ERAD, perhaps there are additional proteins or cofactors
that complete the p97 complex at the mitochondria that
have yet to be discovered. In addition, it is also possible that
diﬀerent factors contribute to regulate MAD under normal
versus stress conditions. Although we do not yet have a clear
understanding of the mitochondrial UPS, the studies to date
suggest that multiple independent pathways work in parallel
to facilitate the protease-mediated degradation of impaired
proteins that reside in, or are en route to, the mitochondria.
2.4. Components of the UPS at Mitochondria. The hypoth-
esized pathway to regulate mitochondrial health can be
further understood by examining individual components
of the UPS system, in particular, the E3 ubiquitin ligases.
The human genome encodes for ∼617 putative E3 ubiquitin
ligases[37].TheseE3sareclassiﬁedintoseveralfamilies,with
RING ﬁnger and BTB proteins being the most abundant in
mammalian systems. Since we know that ERAD is driven
by ER membrane spanning RING domain E3 ligases, the
presence of similar E3s on the OMM would lend support
to the MAD pathway. Indeed, a subcellular localization
screen of 54 human RING-containing E3 ligases found
nine that localized to the mitochondria [38]. Two of these
nine, MITOL and MULAN, have been well documented in
regulating mitochondrial activity. As shown by Yonashiro
etal.,MITOLubiquitinatestwomitochondrialﬁssionfactors
Drp1 and Fis1 [39]. A study on MULAN, an NF-kappaB
activator, revealed that it regulates mitochondrial dynamics
and signalling [37]. While RING ﬁnger E3 ligases are4 Parkinson’s Disease
important for ERAD, they might not be a requirement for
ubiquitination at the mitochondria. As a case-in-point Mule
is an HECT domain containing E3 ligase that ubiquitinates
the OMM protein Mcl1 at 5 lysines [40]. Clearly mitochon-
drial ubiquitin dynamics will be crucial in regulating aspects
of mitochondrial biology and cellular metabolism.
2.5. Deubiquitinating Enzymes: Crucial Players in the UPS.
Ubiquitin conjugation can be reversed by a conserved
family of deubiquitinating enzymes (DUBs). Currently, 79
DUBs have been identiﬁed in the human genome that are
predicted to be eﬀective in counteracting the activity of
E3 ubiquitin ligases [41]. These DUBs have been classiﬁed
into ﬁve families, primarily based on structure. They are:
the ubiquitin-speciﬁc proteases (USPs), the ubiquitin C-
terminal hydrolases (UCHs), the ovarian tumour proteases
(OTUs), the Machado-Joseph disease protein domain pro-
teases (MJDs), and the JAMM motif proteases (JAMMs)
[42].
A wide range of functions have been ascribed to these
deubiquitinases, including (i) generating free ubiquitin from
ubiquitin precursors, (ii) rescuing proteins from degrada-
tion, (iii) editing the ubiquitin biochemical signal, and (iv)
recycling ubiquitin from proteasomal substrates [43]. These
speciﬁc functions enable DUBs to participate in several
cellular pathways, including proteolysis, kinase signalling,
cell cycle, DNA repair and endocytosis [44]. For example,
the three proteasomal DUBs, POH1, USP14 and UCH37,
regulate chain lengths, and remove or process ubiquitin so
that it is not degraded along with the substrate [45]. Hence,
these proteases can rescue proteins and also maintain a
steady level of ubiquitin in the cell (Figures 1(a) and 1(b)).
Two DUBs, A20 and CYLD, have been well characterized
with respect to the NF-kappaB signal transduction pathway,
which is required for inﬂammation and immune responses
[46]. A20 and CYLD deubiquitinate K63-linked polyubiqui-
tinated proteins and consequently downregulate signalling
[47, 48]. Several DUBs, such as BAP1 and USP44, have
been linked to cell cycle regulation [49, 50], while USP1,
USP11, and USP28 are important for DNA repair [51–53].
The regulatory role of DUBs in diverse cellular processes has
implicated them in many types of cancer and neurological
diseases [54].
There are several layers of speciﬁcity that enable DUBs to
carryouttheirbiochemicalactivities.DUBshavebeenshown
to exercise speciﬁcity based on ubiquitin linkage types and
also protein substrates. The above-mentioned USP14, for
example, selectively cleaves K48-linked polyubiquitin chains
[55]. USP14 activity is important for adequate monoubiqui-
tin levels at pre- and postsynaptic terminals [56]. Moreover,
a mutation in USP14, associated with ataxia, has been shown
tocausedefectsinsynaptictransmissionthatleadtoparalysis
and early death in mice [57]. On the other hand, BAP1 is
an example of a substrate-speciﬁc DUB that regulates cell
proliferation by directly binding to host cell factor-1 and
removing its ubiquitin chains [58]. In addition, DUBs can
selectively hydrolyse ubiquitin from the ends (exo), from
within (endo), or from monoubiquitinated substrates [43].
This versatility in substrate recognition reﬂects the means
by which DUBs can perform more than one function in
multiple cellular pathways. The complexity and elegance of
thisreversiblemodiﬁcationunderscorethepotentialrolesfor
DUBs in regulating important cellular outputs.
2.6. Mitochondrial-Associated Deubiquitinases. At present,
four mitochondrial-associated DUBs have been identiﬁed.
The ﬁrst of these to be identiﬁed was USP30, a member of
the USP family that resides in the OMM. Nakamura and
Hirose reported that USP30 is an integral membrane protein
with an N-terminal transmembrane (TM) domain and C-
terminal catalytic domain that faces the cytosol [59]. This
orientation provides access to substrates on the OMM and
the cytosol. Their study also showed that the downregulation
of USP30 by RNAi leads to elongated and interconnected
mitochondria; thus, it can be deduced that the DUB plays a
direct or indirect role in regulating mitochondrial dynamics.
Although speciﬁc substrates have not been identiﬁed, USP30
can cleave both K48- and K63-linked ubiquitin chains [60].
Furthermore, it has recently been shown to interact with
p97 [35], which suggests that it may participate in the MAD
pathway.Takentogether,theseobservationsimplicateUSP30
in more than one mitochondrial directed activity.
In addition to USP30, USP36 is another DUB that local-
izes to the mitochondria, albeit not exclusively. It is primarily
localized to the nucleoli, where it regulates nucleolar activity
through several protein substrates, such as nucleophos-
min/B23 and ﬁbrillarin [61]. Recently, it was found that
USP36 also localizes at the mitochondria and that it has
as t r o n ga ﬃnity for mitochondrial manganese superoxide
dismutase(SOD2)[62].Morespeciﬁcally,theoverexpression
of USP36 decreases the level of polyubiquitinated SOD2
and as a result stabilizes and extends the half-life of SOD2.
These two examples clearly implicate the DUB proteases in
the regulation of both the activity and the health of the
mitochondrion.
Another member of the same family, USP9x, also par-
tially localizes to the mitochondria. It enhances the stability
of Mcl1, the previously described antiapoptotic OMM pro-
tein, by cleaving K48 polyubiquitin chains [63]. USP9x is the
human ortholog of the Drosophila DUB, Faf, which was the
ﬁrst DUB linked to cell diﬀerentiation in the nervous
system [64]. Like Faf, USP9x is thought of be involved in
neuronal fate determination and synaptic function through
its interaction with epsin-1 [65]. Interestingly, USP9x pro-
tein expression was altered in a 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-(MPTP-)
induced PD mouse model study that measured protein
abundance changes, suggesting that it might be associated
with neurodegeneration [66]. While these are compelling
indications that these important proteases play key roles in
mitochondrial function, more work is needed to establish
the role of DUBs at the mitochondria and in the nervous
system.
Finally, a small pool of the Machado-Joseph disease-
associated protein, ataxin-3 also localizes at the mitochon-
dria[67].Ataxin-3hastheabilitytocleavemultipleubiquitinParkinson’s Disease 5
chain types, including K6, K27, K29, K48, and K63, although
it has a preference for K63-linked polyubiquitin [68, 69].
It interacts with Parkin, a Parkinson’s disease-linked E3
ligase, to counteract several types of ubiquitin conjugations.
Hence, it is likely that ataxin-3 edits ubiquitin chains to
target Parkin to diﬀe r e n tc e l l u l a rp a t h w a y ss u c ha sD N A
repair and autophagy (see Section 3). In a Drosophila study,
ataxin-3 exhibited neuroprotective properties by suppressing
polyglutamine-related neurodegeneration [70]. It has not
yet been determined whether ataxin-3 possesses similar
characteristics within mammalian systems, but again these
data provide exciting evidence for DUB activity in regulating
neuronal outputs.
Deubiquitinases may function at the mitochondria via
multiple mechanisms. Like mitochondrial E3 ligases, DUBs
might reside in the OMM (Figure 2(a)). But this is only
probable for DUBs that contain a TM domain. At present,
there are only two with predicted TM domains; interestingly
one of them is USP30 (the other is USP19). Alternatively,
DUBs may be directly targeted to the mitochondria by their
OMM substrates (Figure 2(b)). Three of the above-discussed
deubiquitinases, USP36, USP9x, and ataxin-3, likely belong
in this category as they appear to be substrate speciﬁc.
However, considering that there are relatively few DUBs
available to oppose the function of over 600 E3 ligases,
it is unlikely that all DUBs are substrate speciﬁc. A third
possibility may exist whereby deubiquitinases are anchored
to the mitochondria through interactions with nonsubstrate
proteins. Individual proteins or a complex at the OMM
could stabilize a DUB, bringing it in close proximity to
its substrates (Figure 2(c)). In support of this model, the
domain architecture of most DUBs reveals the presence of
multiple domains that could mediate such protein-protein
interactions [43]. Finally, certain cellular conditions, such as
ROS-induced stress, may act as signals to recruit cytoplasmic
DUBs to the mitochondria (Figure 2(d)). To summarize, the
data on mitochondrial-associated DUBs implicates them in
a varied array of mitochondrial and cellular activities.
2.7. Future Perspectives on DUBs and Mitochondrial Func-
tion in Health and Disease. As advances in the ﬁeld of
mitochondrial protein quality control unravel the roles of
the UPS at the mitochondria, another fascinating area that
deserves more investigation is the process of deubiquitina-
tion. For known mitochondrial deubiquitinases, like USP30,
biochemical and cell-based techniques should be used to
identify the substrates to understand the downstream phys-
iological signiﬁcance and the pathways that are regulated by
these proteases. Furthermore, DUB genomic and proteomic
studies can be used to discover additional mitochondrial-
associated DUBs. One such comparative proteomic study
identiﬁed 6 DUBs that are predicted to localize to the
mitochondria (Table 1); none of which have been conﬁrmed
[41]. Future studies should be aimed at validating these
ﬁndings.
In addition to identifying and characterizing individual
players: mitochondrial DUBs and their substrates, it is im-


















Figure 2: Potential mechanisms to direct deubiquitination at
the mitochondria. The diagram illustrates the multiple ways in
which DUBs may function at the mitochondria. (a) DUBs such
as USP30 can reside in the OMM, in an orientation that provides
access to ubiquitin-modiﬁed OMM proteins. (b) Substrate-speciﬁc
DUBs, like USP9x and ataxin-3, might be directly recruited to the
mitochondria by their substrates, Mcl1 and Parkin, respectively. (c)
It is also possible that DUBs are aﬃxed at the membrane through
protein interactions with nonsubstrate proteins at the OMM. This
arrangement can bring deubiquitinases in close proximity to their
substrates. Although DUBs that use such a mechanism have not
yet been identiﬁed, the ﬁnding that most DUBs contain multiple
protein-protein interaction domains lends support to this view. (d)
Certaincellularconditions,suchasROS-inducedstress,mayrecruit
cytoplasmic DUBs to the mitochondria to counteract the damage.
involved in. There are several yet uncharacterized stages
within mitochondrial pathways where DUBs can intersect
(Figure 5). For instance, DUBs may monitor the activity of
mitochondrialE3sandhenceregulateproteinqualitycontrol
by the proteasome. It is also possible that SUMO-speciﬁc
DUBsactatthemitochondriainordertoregulatemitochon-
drial ﬁssion, while other DUBs may inﬂuence mitochondrial
fusionfactors,andthus,balancemembranedynamicsevents.
With these proposed roles, it is evident that the scope
and relevance of DUBs as regulators of ubiquitin-mediated
pathways is only beginning to emerge. In the even bigger
picture, we note that DUBs are involved in several central
mitochondrial metabolic pathways (Figure 6). Metabolism is
currentlyundergoingarenaissancebasedonthefactthatsev-
eral developmental programs (like cellular diﬀerentiation)
and several human diseases (like cancer) are orchestrated
by fundamental changes in the metabolome. The mitochon-
drion, and the functions highlighted in Figure 6,l i k e l ys e rv e s
as a central platform to integrate signalling pathways that
impactdiversecellbiologicaloutputs.Itishopedthatfurther
study on mitochondrial DUBs will enhance our current
understanding of mitochondrial dysfunction.6 Parkinson’s Disease
Table 1: Functions of known and predicted mitochondrial DUBs.
DUB Function(s) Reference(s)
Ataxin-3 Protein quality control; mitophagy; neuroprotective properties [68, 70–72]
USP9x Cell diﬀerentiation and survival; synaptic function [63, 65]
USP30 Mitochondrial membrane dynamics [59]
USP36 Nucleolar structure and function; oxidative stress [61, 62]
JOSD1 Unknown
USP2 NF-kappaB signalling; AIF-mediated cell death [73, 74]
USP16 Histone deubiquitination; gene expression [75]
USP29 Oxidative stress [76]
USP44 Cell cycle regulation [50]
USP50 Cell cycle regulation [77]
3. Mitophagy
3.1. The Role of Proteolysis in Regulating Mitophagy. Mito-
chondria are the major sites of ROS production in the cell,
and this working-place hazard has created the need for
several quality control systems. The most recently identiﬁed
and characterized pathway is the PINK1/Parkin pathway.
This pathway has received much attention as the key
molecules are well-known PD-linked genes, and this has
directly implicated dysregulated mitochondrial function as
a potential cause and therefore therapeutic target for the
treatment of PD.
3.2. PINK1, Parkin, and Mitophagy. As mitophagy is a mito-
chondrial quality control system, its failure is thought to
trigger the degeneration of neurons, which is considered a
hallmark of PD. Although most cases of PD are sporadic,
about 10% of cases are genetically inherited [78]. Detailed
genetic studies on these cases have provided further evidence
to strengthen the relationship between mitophagy and PD.
Speciﬁcally, researchers have identiﬁed that the products
of the PD-linked genes, Park 2 and Park 6, are involved
in the mitophagy pathway. Park 2 encodes Parkin, an
E3 ubiquitin ligase, which as previously mentioned is an
important component of the UPS [79, 80]. Park 6 encodes a
mitochondrial kinase PTEN-induced kinase 1 (PINK1) that
plays a role in regulating stress-induced apoptosis and mito-
chondrial morphology [81–85]. These two proteins have
been proposed to function together to mediate the removal
of mitochondria by mitophagy as detailed below [86–88].
Studies on both PINK1 mutant Drosophila and mouse brains
revealedspeciﬁcfunctionaldefectsincomplexIactivity[89];
the same defect in complex I activity has also been found
in Parkin-mutant zebraﬁsh [90]. Human neurons lacking
PINK1 demonstrate features of marked oxidative stress
with widespread mitochondrial dysfunction and abnormal
mitochondrial morphology [91]. Interestingly, deﬁciency of
mitochondrial complex I and excessive oxidative damage are
frequently observed in neurons of sporadic PD patients [92].
In fact, impairment of mitochondrial quality control, such
as mitophagy, has been recently proposed to be one of the
mechanisms that trigger the neurodegenerative process [4].
Together, these ﬁndings suggest that common mechanisms
may underlie both familial and sporadic forms of PD, and
impaired mitochondrial clearance could be one such mecha-
nism. Thus, understanding how PINK1 and Parkin mediate
and regulate mitophagy may provide valuable insight into
PD pathogenesis in both forms of the disease.
3.3. Parkin Translocates to Damaged Mitochondria to Initiate
Mitophagy. Undernormalconditions,Parkinlocalizesinthe
cytoplasm. However, upon the induction of mitochondrial
depolarization, Parkin translocates from the cytoplasm to
the mitochondria [93]. This translocation has been shown to
be very selective, occurring only for damaged mitochondria,
but not healthy ones [94]. Since we know that Parkin
accumulates on damaged mitochondria and is required for
their clearance, it is proposed that Parkin mediates a quality
control pathway in order to maintain the ﬁdelity of the
mitochondrial network [17].
When recruited to damaged mitochondria, Parkin medi-
ates the ubiquitination of several of its substrates located on
the OMM [12]( Figure 3). To date, 5 Parkin mitochondrial
substrates have been identiﬁed: mitofusins 1 and 2, voltage-
dependent anion channel, ﬁssion 1, and Tom 20 [29, 95–97].
By ubiquitinating these substrates, Parkin has been proposed
to mediate mitophagy using two mechanisms. First, ubiqui-
tination of these OMM localized proteins serves as a signal to
recruit autophagosomes to the damaged mitochondria [12].
In the second mechanism, Parkin-dependent ubiquitination
could lead to the degradation of its substrates via the UPS
[12]. Degradation of its profusion substrate, mitofusin 1, for
instance, will lead to mitochondrial fragmentation, making
mitochondria more susceptible to mitophagy [29, 95, 98].
Taken together, these ﬁndings suggest that Parkin could be
a link between the UPS and the ALP, two distinct protein
degradation systems in cells. Interestingly, beside its function
in the mitochondrial quality control pathway, Parkin has
also been proposed to play a role in maintaining normal
mitochondrial energy metabolism. In mouse models, gene
deletion of Parkin results in a reduction in mitochondrial
respiration and an increase in oxidative damage [99]. Future
studies on the roles of Parkin in both pathways will help to
elucidate the connection between these pathways as well as

















Figure 3: The PINK1/Parkin pathway mediates mitochondrial
elimination via mitophagy. Accumulation of ROS and other toxic
molecules can damage mitochondria, resulting in the loss of
mitochondrial membrane potential and eventually the reduc-
tion in mitochondrial ATP concentration. Loss of mitochondrial
membrane potential triggers the accumulation of PTEN-induced
kinase 1 (PINK1) on the mitochondrial outer membrane (OMM).
The accumulation of PINK1 recruits the cytoplasmic E3 ubiquitin
ligase, Parkin, to the damaged mitochondria. The mechanism of
this recruitment is still unclear; however, several models have been
proposed, in which the substrates shared by PINK1 and Parkin
may play a role in mediating their interaction. Once on the mito-
chondria, Parkin ubiquitinates various OMM proteins, including
the mitochondrial profusion protein, mitofusin 1. Polyubiquitin
chains on these proteins serve as a signal for the recruitment
of the autophagosome that engulfs and degrades the damaged
mitochondrion through a process called mitophagy.
3.4. Parkin Is Recruited by PINK1 to Damaged Mitochon-
dria. Studies in ﬂy models have revealed that PINK1 and
Parkin function in the same genetic pathway [100]. This
interaction has been extended to mammalian systems,
as several independent groups have shown that PINK1’s
activity is required for the translocation of Parkin [101–
103].Interestingly,mitochondrialaccumulationofPINK1or
just overexpression of PINK1 can result in the translocation
of Parkin and thus mitophagy, even in the absence of
mitochondrialuncouplers[88,94,104].Inthecurrentmodel
(as illustrated in Figure 3), upon mitochondrial depolar-
ization, PINK1 recruits Parkin to damaged mitochondria
and induces their removal by mitophagy [17, 105]. In
addition to cooperatively functioning with Parkin in the
mitophagy pathway, PINK1 has been proposed to also play
importantrolesinmitochondrialenergymetabolism.PINK1
deﬁciency or PD-linked mutations impair the function of
the mitochondrial respiratory chain complex I, resulting
in elevated oxidative damage and increased sensitivity to
apoptotic stress in mammalian cells and tissues [106, 107].
Recently, using a Drosophila model, Liu et al. proposed that
PINK1 regulates the oxidative phosphorylation machinery
via mitochondrial ﬁssion [108]. By participating in multiple
pathways, PINK1 could serve as an important link between
mitophagy, apoptosis, and cellular metabolism.
Even though there are a large number of studies on the
PINK1/Parkinpathwaythathavebeenpublishedrecently,the
fundamentalquestionofhowPINK1recruitsParkinremains
unclear. Studies on cellular processing and localization of
PINK1 could lay a path to a more clear understanding
of PINK1/Parkin-mediated mitophagy. In addition, PINK1
selectively accumulates on damaged mitochondria to recruit
Parkin; however, little is known about how this selectivity is
achieved. Recent studies on the proteolysis of PINK1 have
provided some insights into this selective accumulation of
PINK1.
3.5. PARL Is a New Player in the PINK1/Parkin Pathway.
PINK1 undergoes proteolysis and rapid proteasomal degra-
dation in many cell types and, as a result, exists at low
levels in a healthy cell [109, 110]. However, upon the loss of
mitochondrialmembranepotential,largeamountsofPINK1
can be detected on the mitochondria [94, 103]. It has been
proposed that the inhibition of the proteolysis of PINK1
could be a mechanism for selective PINK1 mitochondrial
accumulation [81, 89]. Using mouse models, we and other
groups have shown that PINK1 undergoes a presenilin-
associated rhomboid-like (PARL) dependent proteolysis [93,
111–113]. This proteolysis is highly conserved; we had
previouslydemonstratedthatinDrosophilaPINK1iscleaved
by rhomboid-7, which is the PARL homolog [100]. We
further placed the ﬂy PARL in the same genetic pathway as
PINK1/Parkin, strongly implicating this protease in regulat-
ing mitophagy. PARL is not the only protease that cleaves
PINK1 [112–114]; however, under normal conditions, only
the PARL-cleaved PINK1 form is found in the cytoplasm,
where it undergoes rapid proteasomal-dependent degrada-
tion [111]. In addition, in PARL−/− cells, upon CCCP-
induced mitochondrial depolarization, Parkin recruitment
and mitophagy are both impaired [111]. Taken together,
these data strongly suggest that PARL could be a regulatory
member of the PINK1/Parkin mitophagy pathway.
PARL dysfunction has been previously linked to PD,
through its roles in maintaining normal mitochondrial func-
tion, regulating apoptosis and mitochondrial morphology
[115, 116], and now this linkage is strengthened by its
role in mitophagy. Hence, understanding how PARL is
regulated may provide us with some valuable insight into the
mechanism of PD.
TheregulationofPARLisnotfullyunderstood,butPARL
undergoes a self-regulated proteolysis at the N-terminus,
known as β-cleavage. This cleavage event is known to
regulatePARL’sactivity[117,118].Interestingly,thiscleavage
is regulated by phosphorylation of PARL’s N-terminus, and
the amino acid residue serine (77) is required for this
cleavage [117]. We have recently identiﬁed a PD-linked
mutation that results in a substitution of this serine to
asparagine, which abolishes β-cleavage [111]. Interestingly,
expression of this mutant PARL cannot rescue the Parkin
recruitment defect found in PARL−/− cells [111]. Together,8 Parkinson’s Disease
these ﬁndings suggest a potential role of β-cleavage in
the PINK1/Parkin pathway. Thus, how β-cleavage regulates
PARL’sactivitycouldbeaninterestingareatostudytofurther
understand mitophagy as a mechanism of disease in PD.
3.6. How Does Proteolysis Regulate Mitophagy? Since β-cleav-
age is a vertebrate-speciﬁc process, it may carry some unique
functions in higher organisms [117]. It has been shown
that β-cleavage is required for mitochondrial fragmentation
induced by PARL [118]. Since mitochondrial fragmentation
promotes mitophagy [30, 119], we propose that the β-
cleavage of PARL may regulate mitophagy (Figure 4). A
product of β-cleavage, a short nuclear-targeted peptide
pβ, has been shown to increase the level of PARL and
proteins that are involved in mitochondrial biogenesis
[120], suggesting that β-cleavage could be a mechanism
that cells adopt to overcome mitochondrial damage. Upon
mitochondrial damage, β-cleavage may promote the elim-
ination of damaged mitochondria by isolating them from
the rest of the mitochondrial network by fragmentation. In
parallel, β-cleavage also generates pβ that upregulates the
expression of genes responsible for mitochondrial biogenesis
(Figure 4(b)). To test this hypothesis, future studies should
focus on elucidating how β-cleavage regulates PARL’s activity
and its downstream eﬀects on mitochondrial morphology
and mitophagy.
Following β-cleavage, PARL has been proposed to
undergo another cleavage called γ-cleavage [121]. Γ-cleavage
occurs in a β-cleavage-dependent manner; the cleavage
generateswhatisbelievedtobeacatalyticallydeadrhomboid
domain and PARL’s ﬁrst transmembrane domain, TMA
[121]. The functional signiﬁcance of γ-cleavage has not been
well established. Given the potential role of β-cleavage in
mitophagy [111], we hypothesize that γ-cleavage could also
play a role in mitophagy by inﬂuencing the selective PINK1
accumulation on mitochondria, one possible mechanism
is that, upon mitochondria damage, PINK1 is anchored
and stabilized by the catalytically dead rhomboid domain
(Figure 4(b)). Thus, it would be interesting to study the
functions of the rhomboid domain and TMA, in the context
of mitophagy.
The yeast PARL ortholog, Rbd1/Pcp1, catalyzes an ATP-
dependent proteolysis of Mgm1 that releases its soluble
form into the intermembrane space [122–124]. In mam-
mals, it is still unclear whether PARL cleaves its substrate
in a similar manner. However, there is some evidence
suggesting that PARL is involved in regulating cellular
metabolism.DownregulationofPARLinhumanmusclecells
results in reduced oxygen consumption, increased oxida-
tive damage, and impaired insulin signalling, suggesting
PARL could be a factor in determining oxidative capacity
[120]. As mentioned earlier, β-cleavage is regulated by
the phosphorylation of three amino acid residues at the
PARL N-terminus [118]. In mitochondria, the only known
kinase/phosphatase pairs are the pyruvate dehydrogenase
kinase/phosphatase and the branched-chain keto-acid dehy-
drogenase kinase/phosphatase, which are involved in regu-
lating proteins in energy production [125, 126]. Thus, future
studies should focus on identifying kinase/phosphatase pairs
that regulate β-cleavage. This will lead to a better under-
standing of the regulation of PARL and perhaps also reveal
new functions for it in other cellular processes. If the reg-
ulation of β-cleavage is indeed linked to the mitochondrial
energy state, we would hypothesize that PARL could sense
changesinthemitochondrialenergystate,suchasATPlevels,
and trigger β-cleavage and sequential γ-cleavage, in order to
ensure the well-being of the mitochondrial population via




in multiple ways. The UPS has been directly linked to
sporadic forms of PD, where UPS failure is associated
with an accumulation of alpha-synuclein, a hallmark of the
disease [127]. It has been established that the proteasome
is responsible for the degradation of alpha-synuclein [128];
proteasomal inhibition leads to synuclein inclusions in the
cytoplasm [129]. Furthermore, SN dopaminergic neurons of
PD patients show reduced expression of the 20S proteasomal
alpha-subunit,incomparisontoage-matchedcontrols[130].
Although the alpha-subunit is not responsible for enzymatic
activity, it is required for proteasomal stability and function.
Inaddition,itisalsopossiblethatUPSimpairmentindirectly
elicits neuronal cell death and triggers PD, by contributing
to mitochondrial dysfunction. Altered proteasomal structure
and function were observed in both familial and sporadic
f o r m so fP D[ 127]; hence, the UPS is most likely a key factor
in the pathogenic process of the disease.
The dysregulation of the UPS and the ALP can also con-
tributetootherneurodegenerativediseases,suchasAlzheim-
er’s disease (AD). Numerous genetic and biochemical studies
have reported the involvement of the UPS in AD pathogene-
sis [131, 132]. More speciﬁcally, there is evidence linking two
hallmark lesions of AD, extracellular plaques, and intracellu-
lar neuroﬁbrillary tangles (NFTs), to the UPS. Extracellular
plaques are mainly formed by amyloid-beta peptides [133],
while NFTs consist of the microtubule-associated protein
tau [134]. Amyloid-beta ﬁber formation has been shown
to impair normal proteasomal function [135, 136], which
in turn facilitates the accumulation of tau, a proteasomal
substrate [131]. Hence, the malfunctioning UPS appears to
be both a consequence as well as a contributing factor, with
respect to AD.
As mentioned earlier, during the ﬁnal step of autophagy,
the contents of the autolysosome are recycled by autolyso-
somal proteolysis. Interestingly, in AD, the ﬁnal proteolysis
stage of the autophagy pathway is defective [137, 138],
suggesting that ALP failure is a factor in the development of
AD-relatedneurodegeneration.Theseﬁndingsaresupported
by genetic studies on AD that examined presenilin-1 (PS1)
mutations, which are the most common cause of early-onset
familial AD (FAD). PS1 is responsible for the activation of
lysosomal proteases during autophagy [139, 140]. PS1-null



























































Figure 4: Proposed model for how PARL regulates PINK1 localization under normal conditions and during stress. (a) In a healthy
mitochondrion, newly synthesized PINK1 is imported by the TOM/TIM complex. Once it is tethered to the inner mitochondrial membrane
(IMM),PINK1is eﬀectively cleaved by the mitochondrial rhomboidprotease PARL,which associates with the TOM/TIMprotein-importing
machinery.ThisPARL-dependentcleavagereleasesPINK1intotheintramembranespace(IMS).ThecleavedPINK1isthenretrotranslocated
to the cytoplasm, where it undergoes rapid proteasomal degradation. Normal mitochondrial ATP levels facilitate the phosphorylation of the
PARL N-terminus. These phosphorylations inhibit the self-regulated proteolysis (β-cleavage) that releases the PARL N-terminal domain. (b)
During stress, such as accumulation of ROS and the depolarization of mitochondrial membrane potential, mitochondrial ATP levels drop
signiﬁcantly as a result of an inhibition of the electron transport chain. Reduced ATP levels result in the dephosphorylation of the PARL N-
terminus,whichleadstoβ-cleavage. β-cleavagegeneratesashortnuclear-targeted peptide,pβ,whichactivatestheexpressionofseveralgenes
involved in cell metabolism and mitochondrial biogenesis. Another product of β-cleavage, the N-terminal cleaved PARL, then undergoes
another cleavage at the loop connecting its ﬁrst and second transmembrane domains. This cleavage, known as γ-cleavage, separates the ﬁrst
transmembranedomainfromtherestoftheproteinandleavesacatalyticallydeadPARL.Disruptionofmembranepotentialalsoinhibitsthe
importofPINK1;insteadofbeingimportedtotheIMM,PINK1stallsattheimportmachinery.BecauseofitsassociationwiththeTOM/TIM
complex, the catalytically dead PARL stabilizes PINK1 on the OMM to recruit Parkin. Parkin triggers the recruitment of autophagosomes,
which eliminates the damaged mitochondria through a process called mitophagy. Through other mechanisms, PINK1 may be anchored on
the OMM but with a lower eﬃciency. (c) When β-cleavage is inhibited, PARL retains its uncleaved form even when the mitochondrial ATP
levels are low. Therefore, during stress, PARL with impaired β-cleavage can no longer facilitate the OMM-anchoring of PINK1. Although
PINK1 may be anchored to the OMM by other mechanisms, due to their low anchoring eﬃciency, there will be less OMM anchored PINK1.
As a result, Parkin recruitment to damaged mitochondria as well as subsequent mitophagy will be impaired. As a mitochondrial quality
control system, failure of proper mitophagy would lead to an accumulation of damaged mitochondria and eventually trigger the cell death




























Figure 5: Mitochondrial quality control systems. Mitochondria are dynamic organelles that continually undergo membrane ﬁssion
and fusion events to maintain their integrity. Under mild to moderate stress, ﬁssion facilitates the segregation of damaged areas of
the mitochondrial network, while fusion dilutes damaged elements by combining mitochondrial pools. When the damage is extensive,
mitochondria are removed by mitophagy. In addition, there is increasing evidence indicating that the UPS participates in the turnover of
several OMM and non-OMM proteins. Ubiquitin has been shown to be a key regulator of membrane dynamics and mitophagy. Hence,
it is likely that DUBs also participate at various stages within these mitochondrial quality control pathways, in order to maintain a steady
equilibrium of protein ubiquitination.
FAD caused by PS1 mutations show defects in lysosome
acidiﬁcation and autolysosome maturation [141–143].
To summarize, defects in proteasomal or autolysosomal
function can lead to ineﬃcient protein clearance and, hence,
contribute to the neuronal cell death observed in many
diﬀerent forms of PD and AD. This again points to the key
role of the proteases discussed above in several neurode-
generative etiologies.
4.1. Interplay between Mitochondrial Dysfunction, PD, and
Cancer. Interestingly, there is a strong inverse relationship
between neurodegeneration and cancer that is worth noting.
The major cause for the progression of neurodegenerative
diseases, such as PD, is the death of postmitotic neurons;
conversely, in cancer, the central problem is promiscuous
cell survival. Studies by several groups have reported an
inverse correlation between the risk of developing PD and
cancer [144, 145]. Although further study is required to fully
understand the inverse connection between the two diseases,
thefollowingcouldbeapossiblemechanisticexplanationfor
this query.
N e u r o n sa r et h em a j o rc e l lt y p ea ﬀected in PD; however,
they are not the only post-mitotic cells. What makes them
unique is their high energy demand. Neurons require large
amounts of energy to fulﬁll their normal functions, for
whichtheyrelyonoxidative phosphorylation [2].Asaresult,
impairment in the clearance of damaged mitochondrial
elements by the quality control systems could be fatal and
could lead to neurodegeneration in PD. On the other hand,
cancer cells can survive without mitochondria, since they
generally exhibit increased glycolysis for their ATP needs
[146]. In fact, these cells use mitochondrial clearance as
a strategy to enhance their resistance to programmed cell
death, which is initiated by mitochondrial proteins [147,
148]. Thus, it is not surprising that mutations that impair
mitochondrial clearance would lead to the death of neurons
(and PD), but this lack of mitophagy would prevent cancer
cells from circumventing apoptosis. In other words, because
mitochondrial clearance allows cancer cells to bypass this
checkpoint, the mechanism that contributes to PD also
promotes the death of malignant cells.
5. Overall Perspective
It is clear from the studies outlined above that the UPS has
a profound role in many aspects of mitochondrial biology.
We have highlighted how mitochondrial-associated DUBs
plausibly are novel players in pathways that inevitably lead
to proteasomal degradation. Deubiquitinases also have the
potential to drive the kinetics of other ubiquitin-mediated
pathways such as mitophagy. It is well established that
mitophagy is initiated by the accumulation of PINK1 on the
OMM. Here, we have discussed how PARL aﬀects PINK1
localization under normal versus stress conditions and,
hence, how PARL might add in another layer of regulation
to reﬁne the process of mitophagy.
The UPS and mitophagy are two of multiple quality
control mechanisms that maintain functional mitochon-
dria. These organelles may have adopted diverse reparative
processes so that no one mechanism is overwhelmed at
any given time. It is likely that diﬀerent factors, such as
ATP availability, ROS levels, and mitochondrial membrane
potential, stimulate certain pathways. Both the UPS and
mitophagy require ATP; hence, oxidative phosphorylation
has an inﬂuence on mitochondrial quality control sys-
tems. Conversely, components of mitophagy also inﬂuence
OXPHOS. Mutations in Parkin as well as defects in PINK1
adversely aﬀect mitochondrial respiration. Furthermore,




















































Figure 6: Interdependence of mitochondrial functions. Mitochondria generate ATP energy for the cell with the help of the electron
transport chain. ATP fuels many cellular processes including protein degradation by the 26S proteasome. Hence, the process of oxidative
phosphorylation (OXPHOS) inﬂuences the function of mitochondrial quality control systems. In the reverse direction, components of
the quality control pathways can inﬂuence OXPHOS. Parkin mutants and defects in PINK1 have been shown to reduce mitochondrial
respiration; PINK1 defects impair complex I functionality. In addition, mammalian studies with ataxin-3 mutants showed reduced complex
II activity. Mitochondrial dysfunction can trigger apoptosis. Failures within the quality control system, coupled with an increase in ROS, can
lead to the release of proapoptotic proteins. For example, if suﬃcient amounts of Mcl1 are not maintained due to unrestrained proteasomal
degradation, Bak can facilitate the release of AIF/cytC and induce apoptosis. Hence, it is important for the quality control mechanisms to
function properly in order to prevent unsolicited downstream eﬀects. Overall, the mitochondrial network has to maintain a reﬁned balance
between all of these processes and direct eﬀective metabolic outputs depending on the environmental and/or developmental context.
Considering the high interconnectivity of diﬀerent mito-
chondrial functions, one of the downstream eﬀects of quality
control failure is intrinsic apoptosis. The proper function-
ing of the mitochondrial UPS is required to maintain
suﬃcient levels of antiapoptotic proteins, such as Mcl1.
While,mitophagyisessentialforpreventinganaccumulation
of damaged mitochondria in the cell that could elicit
cell death. To fully understand the larger implications of
mitochondrial quality control systems and mitochondrial
dysfunction, we must consider the contributing factors such
as energy metabolism and the downstream consequences
such as apoptosis (Figure 6). Hence, further studies are
required to investigate mitochondrial UPS and mitophagy
pathways and to understand how perturbations of these
systems relate to overall cellular metabolic states. Because
proteolysis is becoming a central theme in regulating all of
these integrated pathways and, because proteases are ideal
drug targets, there will be intense interest in both academic
laboratories and pharmaceutical companies to understand
the precise molecular pathways of MAD and mitophagy.
New discoveries in these mitochondrial quality control
systems and their roles in overall cell integrity will continue
to enlighten us on the pathogenesis of neurodegenerative
diseases like PD.
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